Postal Ballot Scrutinizer''s Report
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shareholders of Cohance Lifesciences (formerly Suven Pharmaceuticals) approved all five resolutions via postal ballot, with voting concluding on 13 June 2026. The key resolution was the appointment of Mr. Umang Vohra (ex-Cipla CEO) as Chairman from 1 May 2026 and Group CEO from 20 May 2026, which passed with 99.62% support. His remuneration in excess of Section 197 limits was approved with 88.57% support. The 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' (ESOP 2026) received 96.57% approval, along with its extension to unlisted subsidiaries (96.64%) and the ability to grant stock options equal to or exceeding 1% of issued capital annually (88.16%).
This formalizes Mr. Vohra's leadership transition into the company, bringing in seasoned pharma-sector expertise. The ESOP approval gives the company flexibility to attract and retain talent through stock-based compensation, with potential mild dilution if grants approach the 1% threshold. For shareholders, the results indicate strong institutional and promoter backing for the new leadership, though the ESOP-related resolutions saw notable opposition from some institutional investors.